Reldesemtiv (CK-2127107)

Drug Name: Reldesemtiv (CK-2127107)
Company: Cytokinetics
Location: US-California
Website: https://www.fortitude-als.com/
Drug Type: Small Molecule
Conditions: ALS, SMA, and others
Mechanism Type: Improving muscle function
Mechanism: CK-107, is a fast skeletal muscle troponin activator (FSTA), that aims to increase muscle strength and decrease muscle fatigue in part, by slowing the release of calcium bound to the muscle protein, troponin, increasing the force of muscle contraction.
U.S. Status for ALS: Phase II

References:
[1] A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) ClinicalTrials.gov, 5 Feb 2018. Accessed 8 Feb 2018 from https://www.clinicaltrials.gov/ct2/show/NCT03160898?term=cytokinetics&draw=1&rank=2

Last updated February 8th, 2018

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail